Researchers at the University of Oxford developed one of two series and examined samples taken from more than 700,000 participants between December 2020 and August 2021.
This analysis showed that a person who received a second dose of the Pfizer vaccine one month earlier was 90% more likely to be protected from delta variant than a person who was not vaccinated for high viral load infections. This number drops to 85% after two months and to 78% after three months.
67% of people who receive two injections of the AstraZeneca vaccine are protected after one month, 65% after two months, and 61% after three months. After four to five months, the level of protection provided by the two vaccines is similar according to the study, which has not yet been verified by peers.
Dr. Goyan Powells, who worked on the study, explained that these figures “actually indicate a decline” in the effectiveness of the Pfizer vaccine, while for AstraZeneca “differences (month to month) are likely to be linked, i.e. no change in safety”.
The researcher, however, stressed that despite these “small drops in protection”, “the overall effectiveness (of both vaccines) is very high”, stressing that the researchers had read the overall safety and not against strict protection. Forms and hospitals, “two very important data for evaluating the effectiveness of vaccines”.
Several countries, including the United Kingdom, are considering launching a booster campaign with a third dose of the vaccine.
The British government announced at the end of April that it had purchased 60 million new dose Pfizer vaccines to set up a booster program for the most vulnerable people in the fall.
“Music geek. Coffee lover. Devoted food scholar. Web buff. Passionate internet guru.”